Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial
| Autor: | Snoeck-Stroband, J.B., Lapperre, T.S., Sterk, P.J., Hiemstra, P.S., Thiadens, H.A., Boezen, H.M., Hacken, N.H.T. ten, Kerstjens, H.A.M., Postma, D.S., Timens, W., Sont, J.K., GLUCOLD Study Grp |
|---|---|
| Přispěvatelé: | Groningen Research Institute for Asthma and COPD (GRIAC), Lifestyle Medicine (LM), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Life Course Epidemiology (LCE), GLUCOLD Study Grp, Amsterdam institute for Infection and Immunity, Pulmonology |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
AIRWAY INFLAMMATION lcsh:Medicine Severity of Illness Index CORTICOSTEROID TREATMENT Pulmonary function testing Pulmonary Disease Chronic Obstructive Adrenal Cortex Hormones Forced Expiratory Volume Lung volumes lcsh:Science Lung Fluticasone COPD Multidisciplinary medicine.diagnostic_test FLUTICASONE PROPIONATE Middle Aged Bronchodilator Agents LUNG-FUNCTION Phenotype Treatment Outcome Female Salmeterol Engineering sciences. Technology Research Article medicine.drug Spirometry medicine.medical_specialty OBSTRUCTIVE PULMONARY-DISEASE Drug Administration Schedule Fluticasone propionate SALMETEROL Internal medicine Administration Inhalation medicine Humans BETA-AGONIST Aged Asthma business.industry lcsh:R Sputum Placebo Effect medicine.disease respiratory tract diseases EXACERBATIONS Immunology FEV1 DECLINE SPUTUM-EOSINOPHILIA lcsh:Q business |
| Zdroj: | PLoS ONE, 10(12):e0143793. PUBLIC LIBRARY SCIENCE PLoS ONE PLoS ONE, Vol 10, Iss 12, p e0143793 (2015) PLoS ONE, 10(12). Public Library of Science PLoS ONE, 10(12) |
| ISSN: | 1932-6203 |
| Popis: | BACKGROUND:The decline in lung function can be reduced by long-term inhaled corticosteroid (ICS) treatment in subsets of patients with chronic obstructive pulmonary disease (COPD). We aimed to identify which clinical, physiological and non-invasive inflammatory characteristics predict the benefits of ICS on lung function decline in COPD. METHODS:Analysis was performed in 50 steroid-naive compliant patients with moderate to severe COPD (postbronchodilator forced expiratory volume in one second (FEV1), 30-80% of predicted, compatible with GOLD stages II-III), age 45-75 years, >10 packyears smoking and without asthma. Patients were treated with fluticasone propionate (500 μg bid) or placebo for 2.5 years. Postbronchodilator FEV1, dyspnea and health status were measured every 3 months; lung volumes, airway hyperresponsiveness (PC20), and induced sputum at 0, 6 and 30 months. A linear mixed effect model was used for analysis of this hypothesis generating study. RESULTS:Significant predictors of attenuated FEV1-decline by fluticasone treatment compared to placebo were: fewer packyears smoking, preserved diffusion capacity, limited hyperinflation and lower inflammatory cell counts in induced sputum (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|